Page 1

POABIOMED Abiomed Announces Record Revenue of $ 253 Million , Up 53 % Year Over Year August 4 , 2021 Full year global revenue guidance increased for fiscal year 2022 to 22 % -24 % growth versus prior year DANVERS , Mass .-- ( BUSINESS WIRE ) -- Aug . 4 , 2021-- Abiomed , Inc. ( NASDAQ : ABMD ) , a leading provider of breakthrough heart support technologies , today announced financial results for the quarter ended June 30 , 2021 . Q1 financial summary and operational highlights : • Total revenue for the quarter totaled $ 252.6 million , an increase of 53 % compared to $ 164.9 million during the same period of the prior fiscal year , driven by record global patient utilization with COVID recovery . • Worldwide Impella® heart pump product revenue for the quarter totaled $ 241.5 million , an increase of 55 % compared to $ 155.4 million during the same period of the prior fiscal year . • U.S. Impella product revenue for the quarter totaled $ 197.5 million , an increase of 56 % compared to $ 126.2 million during the same period of the prior fiscal year , with U.S. patient usage of Impella heart pumps up 43 % . • Outside the U.S. , Impella product revenue for the quarter totaled $ 44.0 million , an increase of 51 % compared to $ 29.2 million during the same period of the prior fiscal year . Specifically , Japan product revenue for the quarter totaled $ 10.9 million , an increase of 24 % compared to $ 8.8 million during the same period of the prior fiscal year , driven by a 78 % increase in patient usage . • Gross margin for the quarter was 82.1 % compared to 78.2 % during the same period of the prior fiscal year . • The company announced the acquisition of the remaining interest of preCARDIA for $ 82.8 million . preCARDIA is the developer of a proprietary catheter and controller that will complement Abiomed's product portfolio to expand options for upstream heart failure patients acutely decompensating . Annually , more than one million patients are admitted to hospitals in the United States with acute decompensated heart failure ( ADHF ) 1 . Despite available pharmaceutical treatments , heart failure is the leading cause of hospitalization in patients older than 65 years of age² . preCARDIA will provide heart failure specialists a minimally invasive solution with the potential to improve patient outcomes and lower the cost of care by providing early intervention with this new technology . • Non - GAAP income from operations * increased 94 % to $ 66.2 million , or 26.2 % non - GAAP operating margin * for the quarter , compared to $ 34.1 million non - GAAP income from operations , or 20.7 % GAAP operating margin during the same period of the prior fiscal year . GAAP loss from operations for the quarter was $ 49.3 million , or ( 19.5 % ) GAAP operating margin primarily due to the accounting for the preCARDIA acquisition . • Non - GAAP net income * increased 95 % to $ 51.1 million , or $ 1.10 per diluted share , compared to non - GAAP net income of $ 26.1 , or $ 0.58 per diluted share during the same period of the prior fiscal year . GAAP net loss for the quarter was $ 26.5 million , or $ ( 0.59 ) per diluted share compared to GAAP net income of $ 44.6 million , or $ 0.98 per diluted share during the same period of the prior fiscal year primarily due to the accounting for the preCARDIA acquisition . • The company generated operating cash flows of $ 55.4 million during the quarter . As of June 30 , 2021 , the company had $ 804.8 million of cash and cash equivalents and marketable securities and no debt . • On June 29 , the company announced Impella RP with SmartAssist received U.S. Food and Drug Administration ( FDA ) pre - market approval ( PMA ) as safe and effective to treat acute right heart failure for up to 14 days . Impella RP with SmartAssist is the first single - access temporary percutaneous ventricular support device with sensor technology . The FDA issued an emergency use authorization ( EUA ) for Impella RP in June 2020 to include patients suffering from COVID - 19 related right heart failure or decompensation , including pulmonary embolism ( PE ) . Since the onset of the COVID - 19 pandemic , Impella RP has become a therapeutic choice for clinicians treating certain COVID - 19 patients suffering right heart failure . • On August 2 , the Centers for Medicare and Medicaid Services ( CMS ) released final Medicare payment levels for inpatient hospital discharges for fiscal year 2022 which takes effect October 1 , 2021. Consistent with the April 2021 proposal and the Form 8 - K filed with the SEC , CMS will reassign select ICD - 10 - PCS codes from MS - DRG 215 to additional cardiovascular related MS - DRGs to align clinical populations and better reflect hospital resources . We are pleased and